Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07117851) titled 'A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Extramammary Paget Disease
Scrotum Disease
Intervention:
Drug: Disitamab Vedotin combined with Bicalutamide
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: August 1, 2025
Target Sample Size: 20
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/sho...